Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 956 participants.
Also called NCT07653477
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 956 participants
- Registry
-
NCT07653477
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07653477. Randomized; no masking; primary purpose treatment. Start 2026-09-07 (actual); primary completion 2028-02-29 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)
- Acronym
- UNIGUIDE-2
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- UBT251 Injection 2.0 mg group
- Intervention (Drug)
- UBT251 Injection 4.0 mg group
- Intervention (Drug)
- UBT251 Injection 6.0 mg group
- Intervention (Drug)
- Semaglutide Injection
- Lead sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Record details
- Record id
cardio:ct-nct07653477- Content hash
4bff62d8281c6fccb1b67f3365aaa6b0f25d5c05bf43fea1c6c4f8e3c10c2aa5